Abstract: Toll-like receptor (TLR) agonists can induce chemokine production. We find that TLR2 and TLR6 are widely expressed on human melanoma cells, and that TLR2/6 agonists (MALP-2 or FSL-1) synergize with interferon-gamma (IFN?) to induce production of CXCL10 from melanoma cells. Furthermore, melanoma cells and immune cells freshly isolated from surgical specimens also respond to TLR2/6 agonists +IFN? by upregulating CXCL10 production, compared to treatment with either agent alone. It is also disclosed herein that these compounds are useful in inducing CLXL10 in other types of cancer. Collectively, these data identify a novel synergy of TLR2/6 agonists +IFN? for inducing CXCL10 production directly from melanoma cells, raising the possibility that intratumoral administration of these agents may improve immune signatures in melanoma and have value in combination with other immune therapies, by supporting T-cell migration into melanoma metastases.

Abstract: An insertion tongue of the retractor device may be pushed into the subject through the trocar incision, along one side of the organ. The tip of the insertion tongue pushes the impacted organ and its endoscopic recovery bag slightly away from the cavity wall. A scalpel is passed through the insertion guide with the tip of the scalpel blade in the retention guide on the back of the insertion tongue, and with the sharp side of the scalpel blade facing away from the organ and from the tongue of the retractor device. The scalpel is then passed down through the cavity wall, with its tip in the retention guide, while tension on the retractor device handle away from the organ, and gentle outward traction on the organ (and bag) permits removal of the organ (and bag) as soon as the opening is just large enough to allow it.

Abstract: Toll-like receptor (TLR) agonists can induce chemokine production. We find that TLR2 and TLR6 are widely expressed on human melanoma cells, and that TLR2/6 agonists (MALP-2 or FSL-1) synergize with interferon-gamma (IFN?) to induce production of CXCL10 from melanoma cells. Furthermore, melanoma cells and immune cells freshly isolated from surgical specimens also respond to TLR2/6 agonists +IFN? by upregulating CXCL10 production, compared to treatment with either agent alone. It is also disclosed herein that these compounds are useful in inducing CLXL10 in other types of cancer. Collectively, these data identify a novel synergy of TLR2/6 agonists +IFN? for inducing CXCL10 production directly from melanoma cells, raising the possibility that intratumoral administration of these agents may improve immune signatures in melanoma and have value in combination with other immune therapies, by supporting T-cell migration into melanoma metastases.

Abstract: The present invention encompasses novel peptides useful for preventing and treating cancer, particularly melanoma. Multiple sequences of interest are provided and these sequences have been incorporated into other peptides to obtain a series of peptides of about 30 amino acid residues in length wherein the properties of each combine to yield an effective cocktail for treating melanoma, which surpasses the use of single peptides as immunogens, as well as shorter peptides as immunogens.

Abstract: The present invention encompasses novel peptides useful for preventing and treating cancer, particularly melanoma. Multiple sequences of interest are provided and these sequences have been incorporated into other peptides to obtain a series of peptides of about 30 amino acid residues in length wherein the properties of each combine to yield an effective cocktail for treating melanoma, which surpasses the use of single peptides as immunogens, as well as shorter peptides as immunogens.

Abstract: An insertion tongue of the retractor device may be pushed into the subject through the trocar incision, along one side of the organ. The tip of the insertion tongue pushes the impacted organ and its endoscopic recovery bag slightly away from the cavity wall. A scalpel is passed through the insertion guide with the tip of the scalpel blade in the retention guide on the back of the insertion tongue, and with the sharp side of the scalpel blade facing away from the organ and from the tongue of the retractor device. The scalpel is then passed down through the cavity wall, with its tip in the retention guide, while tension on the retractor device handle away from the organ, and gentle outward traction on the organ (and bag) permits removal of the organ (and bag) as soon as the opening is just large enough to allow it.

Abstract: The present invention is directed to a newly discovered gene family with multiple isoforms, designated TAG-1, TAG-2a, TAG-2b, TAG-2c, and TAG-3, nucleic acid sequences encoding those proteins, and antibodies generated against said proteins. The genes, proteins, and peptides described herein may be used as diagnostic indicators of the presence of cancer and/or used in therapeutics to treat cancer.